Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Bladder Cancer

  Free Subscription


Articles published in BJU Int

Retrieve available abstracts of 158 articles:
HTML format



Single Articles


    September 2021
  1. GORDON NS, Baxter LA, Goel A, Arnold R, et al
    Urine dna for monitoring chemoradiotherapy response in muscle-invasive bladder cancer: A pilot study.
    BJU Int. 2021 Sep 7. doi: 10.1111/bju.15589.
    PubMed     Abstract available


    August 2021
  2. ELSAWY AA, Abol-Enein H, Laymon M, Ahmed AE, et al
    Predictive Value of Immunological Markers after Bacillus Calmette-Guerin Induction in Bladder Cancer.
    BJU Int. 2021 Aug 27. doi: 10.1111/bju.15582.
    PubMed     Abstract available


  3. FURRER MA, Papa N, Luetolf S, Roth B, et al
    A longitudinal study evaluating interim assessment of neoadjuvant chemotherapy for bladder cancer.
    BJU Int. 2021 Aug 21. doi: 10.1111/bju.15579.
    PubMed     Abstract available


  4. MIYATA Y, Tsurusaki T, Hayashida Y, Imasato Y, et al
    Intravesical MMC and MMC+Ara-C for non-muscle invasive bladder cancer: A randomized clinical trial.
    BJU Int. 2021 Aug 12. doi: 10.1111/bju.15571.
    PubMed     Abstract available


    July 2021
  5. LOTAN Y
    Metabolic syndrome and bladder cancer.
    BJU Int. 2021;128:1-2.
    PubMed    


    June 2021
  6. DIRIE J, Mahesan T, Hart E, Janardanan S, et al
    Delivering safe and timely cancer care during COVID-19: lessons and successes from the transition period.
    BJU Int. 2021;127:633-635.
    PubMed    


    May 2021
  7. JAHNSON S, Soderkvist P, Aljabery F, Olsson H, et al
    TERT mutation and the p53 pathway in T1 urinary bladder cancer.
    BJU Int. 2021 May 24. doi: 10.1111/bju.15490.
    PubMed     Abstract available


  8. MOE A, Liow E, Redfern A, Swarbrick N, et al
    A phase I open label dose-escalation study to evaluate the tolerability, safety and immunological efficacy of sub-urothelial durvalumab injection in adults with muscle-invasive or high-risk non-muscle-invasive bladder cancer (SUBDUE-1, SUB-urothelial
    BJU Int. 2021 May 6. doi: 10.1111/bju.15365.
    PubMed     Abstract available


    April 2021
  9. RAVI P, Pond GR, Diamantopoulos LN, Su C, et al
    Optimal Pathologic Response After Neoadjuvant Chemotherapy For Muscle-Invasive Bladder Cancer: Results From A Global, Multi-Center Collaboration.
    BJU Int. 2021 Apr 28. doi: 10.1111/bju.15434.
    PubMed     Abstract available


  10. COWAN B, Klein E, Jansz K, Westenfelder K, et al
    Longitudinal Follow-up and Performance Validation of a mRNA-based Urine Test (Xpert(R) Bladder Cancer Monitor) for surveillance in Non-Muscle Invasive Bladder Cancer Patients.
    BJU Int. 2021 Apr 1. doi: 10.1111/bju.15418.
    PubMed     Abstract available


    March 2021
  11. STROTHER MC, Kutikov A, Epstein M, Bochner E, et al
    Safety of Neoadjuvant Chemotherapy in Patients with Muscle-Invasive Bladder Cancer and Malignant Ureteral Obstruction.
    BJU Int. 2021 Mar 29. doi: 10.1111/bju.15410.
    PubMed     Abstract available


  12. FICARRA V, Crestani A, Rossanese M, Alario G, et al
    Retrosigmoid ileal conduit without transposition of the left ureter after open radical cystectomy for bladder cancer.
    BJU Int. 2021 Mar 10. doi: 10.1111/bju.15375.
    PubMed     Abstract available


    February 2021
  13. ABRAHAMSSON J, Kollberg P, Almquist H, Blackberg M, et al
    Complete Metabolic Response with FDG-PET-CT Predicts Survival after Induction Chemotherapy in patients with Clinically Node-positive Bladder Cancer.
    BJU Int. 2021 Feb 24. doi: 10.1111/bju.15374.
    PubMed     Abstract available


  14. MIYAKE M, Nakai Y, Nishimura N, Ohnishi S, et al
    Hexylaminolevulinate-mediated fluorescent urine cytology with a novel automated detection technology for screening and surveillance of bladder cancer.
    BJU Int. 2021 Feb 12. doi: 10.1111/bju.15368.
    PubMed     Abstract available


    January 2021
  15. BREE KK, Hensley PJ, Brooks NA, Matulay J, et al
    Impact of upper tract urothelial carcinoma on response to bcg in patients with non-muscle invasive bladder cancer.
    BJU Int. 2021 Jan 22. doi: 10.1111/bju.15344.
    PubMed     Abstract available


  16. DUNSMORE J, Duncan E, Mariappan P, de Bruin M, et al
    What influences adherence to guidance for post-operative instillation of intravesical chemotherapy to bladder cancer patients?
    BJU Int. 2021 Jan 15. doi: 10.1111/bju.15336.
    PubMed     Abstract available


  17. RICHTERS A, Ripping TM, Kiemeney LA, Leliveld AM, et al
    Hospital volume is associated with postoperative mortality following radical cystectomy for treatment of bladder cancer.
    BJU Int. 2021 Jan 6. doi: 10.1111/bju.15334.
    PubMed     Abstract available


  18. FUKUOKAYA W, Kimura T, Yanagisawa T, Kimura S, et al
    Comparison of the Immunotherapy Response Evaluation Criteria in Solid Tumours (iRECIST) with RECIST for capturing treatment response of patients with metastatic urothelial carcinoma treated with pembrolizumab.
    BJU Int. 2021;127:90-95.
    PubMed     Abstract available


    December 2020
  19. STANGL FP, Thalmann GN
    Continent diversion: five decades of developments and evolution.
    BJU Int. 2020;126:653-660.
    PubMed     Abstract available


  20. MUILWIJK T, Akand M, Soria F, Giordano A, et al
    The Cancer of the Bladder Risk Assessment (COBRA) score for estimating cancer-specific survival after radical cystectomy: external validation in a large bi-institutional cohort.
    BJU Int. 2020;126:704-714.
    PubMed     Abstract available


    November 2020
  21. BROOKS NA, Kokorovic A, Xiao L, Matulay JT, et al
    The Obesity Paradox: Defining the impact of Body Mass Index and Diabetes Mellitus for patients with Non-Muscle Invasive Bladder Cancer Treated with Bacillus Calmette-Guerin.
    BJU Int. 2020 Nov 14. doi: 10.1111/bju.15296.
    PubMed     Abstract available


  22. SORIA F, Black PC, Fairey AS, Cookson MS, et al
    Neoadjuvant chemotherapy plus radical cystectomy versus radical cystectomy alone in clinical T2 bladder cancer without hydronephrosis.
    BJU Int. 2020 Nov 5. doi: 10.1111/bju.15289.
    PubMed     Abstract available


  23. DEL GIUDICE F, Leonardo C, Simone G, Pecoraro M, et al
    Preoperative detection of Vesical Imaging-Reporting and Data System (VI-RADS) score 5 reliably identifies extravesical extension of urothelial carcinoma of the urinary bladder and predicts significant delayed time to cystectomy: time to reconsider the
    BJU Int. 2020;126:610-619.
    PubMed     Abstract available


    October 2020
  24. SPENCER-BOWDAGE S, Russell B, Rigby J, O'Kelly J, et al
    The experience of UK bladder cancer patients during the COVID-19 pandemic: A survey-based snapshot.
    BJU Int. 2020 Oct 30. doi: 10.1111/bju.15287.
    PubMed     Abstract available


  25. KARDOUST PARIZI M, Shariat SF, Margulis V, Mori K, et al
    Tumor infiltrating immune cells to predict response to intravesical BCG in Patients with Non-muscle invasive Bladder Cancer: A Systematic Review and meta-analysis.
    BJU Int. 2020 Oct 18. doi: 10.1111/bju.15276.
    PubMed     Abstract available


  26. HOSSEINI A, Mortezavi A, Sjoberg S, Laurin O, et al
    Robot-assisted intracorporeal orthotopic bladder substitution after radical cystectomy: perioperative morbidity and oncological outcomes - a single-institution experience.
    BJU Int. 2020;126:464-471.
    PubMed     Abstract available


    September 2020
  27. LENFANT L, Cancel-Tassin G, Gazut S, Comperat E, et al
    Genetic variability in 13q33 and 9q34 is linked to Aggressiveness Patterns and a Higher risk of progression of Non-Muscle-Invasive Bladder Cancer at the time of Diagnosis.
    BJU Int. 2020 Sep 25. doi: 10.1111/bju.15254.
    PubMed     Abstract available


  28. CACCIAMANI G, Aron M, Gill I, Desai M, et al
    Oncological outcome according to attainment of pentafecta after robot assisted radical cystectomy among bladder cancer patients using KORARC database (730 multicenter robot radical cystectomy database) BJU Int 2020 Jul 8. doi: 10.1111/ bju.15178.
    BJU Int. 2020 Sep 1. doi: 10.1111/bju.15222.
    PubMed     Abstract available


  29. VAN DER VLIES E, Los M, Stijns PEF, van Hengel M, et al
    Preoperative frailty and outcome in patients undergoing radical cystectomy.
    BJU Int. 2020;126:388-395.
    PubMed     Abstract available


    August 2020
  30. KOHADA Y, Hayashi T, Hsi RS, Yukihiro K, et al
    Recurrence and Progression Free Survival of Intermediate Risk Non-Muscle Invasive Bladder Cancer: The impact of Conditional Evaluation and Sub-Classification.
    BJU Int. 2020 Aug 17. doi: 10.1111/bju.15209.
    PubMed     Abstract available


  31. MONTORSI F, Moschini M, Necchi A
    CALIBER: a phase II randomized feasibility trial of chemoablation with mitomycin-C vs surgical management in low-risk non-muscle-invasive bladder cancer.
    BJU Int. 2020 Aug 17. doi: 10.1111/bju.15214.
    PubMed     Abstract available


  32. LEE SH, Mahendran R, Tham SM, Thamboo TP, et al
    Tryptophan/kynurenine ratio as biomarker of bladder cancer.
    BJU Int. 2020 Aug 13. doi: 10.1111/bju.15205.
    PubMed     Abstract available


  33. LEE SH, Mahendran R, Tham SM, Thamboo TP, et al
    Combination Bacillus Calmette-Guerin and indoleamine 2,3-dioxygenase 1 inhibitor therapy of murine orthotopic bladder cancer.
    BJU Int. 2020 Aug 8. doi: 10.1111/bju.15201.
    PubMed     Abstract available


  34. ALJABERY F, Liedberg F, Haggstrom C, Strock V, et al
    Treatment and prognosis of bladder cancer patients with other primary cancers. A nationwide population-based study in the Bladder Cancer Data Base Sweden (BladderBaSe).
    BJU Int. 2020 Aug 6. doi: 10.1111/bju.15198.
    PubMed     Abstract available


  35. GONTERO P, Montanari E, Roupret M, Longo F, et al
    Comparison of the performance of ADXBLADDER test and urinary Cytology in the follow up of Non-Muscle Invasive Bladder Cancer: a blinded prospective multicentric study.
    BJU Int. 2020 Aug 3. doi: 10.1111/bju.15194.
    PubMed     Abstract available


  36. GALLAGHER KM, Bhatt NR, Clement K, Kulkarni M, et al
    Study launch: transurethral REsection and Single instillation intra-vesical chemotherapy Evaluation in bladder Cancer Treatment (RESECT).
    BJU Int. 2020;126:310-311.
    PubMed    


  37. HUSSEIN AA, Elsayed AS, Aldhaam NA, Jing Z, et al
    A comparative propensity score-matched analysis of perioperative outcomes of intracorporeal vs extracorporeal urinary diversion after robot-assisted radical cystectomy: results from the International Robotic Cystectomy Consortium.
    BJU Int. 2020;126:265-272.
    PubMed     Abstract available


    July 2020
  38. OH JJ, Lee S, Ku JH, Kwon TG, et al
    Oncological outcome according to attainment of pentafecta after robot assisted radical cystectomy among bladder cancer patients using KORARC database (730 multicenter robot radical cystectomy database).
    BJU Int. 2020 Jul 18. doi: 10.1111/bju.15178.
    PubMed     Abstract available


  39. ELKASHEF A, Barakat N, Khater SM, Awadalla A, et al
    Effect of Low Energy Shock Wave Therapy on Intravesical Epirubicin Delivery in a Rat Model of Bladder Cancer.
    BJU Int. 2020 Jul 12. doi: 10.1111/bju.15173.
    PubMed     Abstract available


  40. LOTAN Y, Chaplin I, Ahmadi H, Meng X, et al
    Prospective evaluation of blue light flexible cystoscopy with hexaminolevulinate in non-muscle-invasive bladder cancer.
    BJU Int. 2020 Jul 10. doi: 10.1111/bju.15166.
    PubMed     Abstract available


    June 2020
  41. GAKIS G, Karl A, Bertz S, Burger M, et al
    Transurethral en bloc submucosal hydrodissection versus conventional resection for resection of non-muscle invasive bladder cancer (HYBRIDBLUE): a randomized, multicentre trial.
    BJU Int. 2020 Jun 23. doi: 10.1111/bju.15150.
    PubMed     Abstract available


  42. SARI MOTLAGH R, Mori K, Miura N, Quhal F, et al
    The recurrence and progression risk after simultaneous endoscopic surgery of urothelial bladder tumor and benign prostatic hyperplasia; a systematic review and meta-analysis.
    BJU Int. 2020 Jun 21. doi: 10.1111/bju.15146.
    PubMed     Abstract available


  43. HENTSCHEL AE, van EE, der Toom, Vis AN, et al
    A Systematic Review on Mutation Markers for Bladder Cancer Diagnosis in Urine.
    BJU Int. 2020 Jun 15. doi: 10.1111/bju.15137.
    PubMed     Abstract available


  44. MCCLOSKEY H, Hamad J, Smith AB
    How can we motivate patients with bladder cancer to help themselves?
    BJU Int. 2020;125:751-752.
    PubMed    


    March 2020
  45. MANNION L, Bosco C, Nair R, Mullassery V, et al
    Overall survival, disease specific survival and local recurrence outcomes in patients with muscle invasive bladder cancer treated with external beam radiotherapy and brachytherapy: A systematic review.
    BJU Int. 2020 Mar 7. doi: 10.1111/bju.15047.
    PubMed     Abstract available


  46. MOSTAFID AH, Porta N, Cresswell J, Griffiths T, et al
    CALIBER - A phase II randomised feasibility trial of chemoablation with mitomycin versus surgical management in low risk non-muscle invasive bladder cancer.
    BJU Int. 2020 Mar 3. doi: 10.1111/bju.15038.
    PubMed     Abstract available


    February 2020
  47. JANISCH F, Rink M, Shariat SF
    The promise and challenges of neoadjuvant immunotherapy in the management of non-metastatic muscle-invasive bladder cancer.
    BJU Int. 2020 Feb 3. doi: 10.1111/bju.15025.
    PubMed     Abstract available


  48. SAAD M, Moschini M, Stabile A, Macek P, et al
    Long-term functional and oncological outcomes of nerve-sparing and prostate capsule-sparing cystectomy: a single-centre experience.
    BJU Int. 2020;125:253-259.
    PubMed     Abstract available


    January 2020
  49. CHUNG J, Maganti M, Kulkarni GS, Morash R, et al
    Modifiable Lifestyle Behaviours Impact the Health-Related Quality of Life of Bladder Cancer Survivors.
    BJU Int. 2020 Jan 24. doi: 10.1111/bju.15007.
    PubMed     Abstract available


  50. TAN WS, Teo CH, Chan D, Ang KM, et al
    Exploring patients' experience and perception of being diagnosed with bladder cancer: A mixed methods approach.
    BJU Int. 2020 Jan 23. doi: 10.1111/bju.15008.
    PubMed     Abstract available


  51. MATULAY JT, Soloway M, Witjes JA, Buckley R, et al
    Risk Adapted Management of Low-Grade Bladder Tumors: Recommendations from the International Bladder Cancer Group.
    BJU Int. 2020 Jan 16. doi: 10.1111/bju.14995.
    PubMed     Abstract available


  52. MOSSANEN M, Chang SL
    Beyond bladder cancer surveillance: building a survivorship clinic.
    BJU Int. 2020;125:2-3.
    PubMed    


  53. CACCIAMANI GE, Winter M, Medina LG, Ashrafi AN, et al
    Radical cystectomy pentafecta: a proposal for standardisation of outcomes reporting following robot-assisted radical cystectomy.
    BJU Int. 2020;125:64-72.
    PubMed     Abstract available


    October 2019
  54. TAYLOR J, Becher E, Steinberg GD
    Update on the Guideline of Guidelines: Non-Muscle Invasive Bladder Cancer.
    BJU Int. 2019 Oct 9. doi: 10.1111/bju.14915.
    PubMed     Abstract available


    September 2019
  55. JAIN RK, Grivas P, Pal SK
    Non-invasive diagnosis and monitoring of urothelial bladder cancer: are we there yet?
    BJU Int. 2019;124:361-362.
    PubMed    


    August 2019
  56. JUNG A, Nielsen ME, Crandell JL, Palmer MH, et al
    Health-Related Quality of Life among Non-Muscle-Invasive Bladder Cancer Survivors: A Population-Based Study.
    BJU Int. 2019 Aug 5. doi: 10.1111/bju.14888.
    PubMed     Abstract available


  57. FILIPPOU P, Smith AB
    A new horizon for bladder preservation in muscle-invasive bladder cancer.
    BJU Int. 2019;124:184-185.
    PubMed    


    July 2019
  58. MARTINI A, Sfakianos JP, Renstrom-Koskela L, Mortezavi A, et al
    The Natural History of Untreated Muscle Invasive Bladder Cancer.
    BJU Int. 2019 Jul 16. doi: 10.1111/bju.14872.
    PubMed     Abstract available


  59. RAI BP, Bondad J, Vasdev N, Adshead J, et al
    Robotic versus open radical cystectomy for bladder cancer in adults.
    BJU Int. 2019 Jul 15. doi: 10.1111/bju.14870.
    PubMed     Abstract available


  60. HAMPSON A, Vincent A, Dasgupta P, Vasdev N, et al
    Radical cystectomy complications and perioperative mortality.
    BJU Int. 2019;124:3-4.
    PubMed    


    June 2019
  61. MCCLINTOCK TR
    Palliative care in patients with bladder cancer: an opportunity for value improvement?
    BJU Int. 2019;123:913-914.
    PubMed    


  62. DOYLE E, Crew J, Mostafid H, Tuthill M, et al
    Urothelial cancer: a narrative review of the role of novel immunotherapeutic agents with particular reference to the management of non-muscle-invasive disease.
    BJU Int. 2019;123:947-958.
    PubMed     Abstract available


    May 2019
  63. MAZZONE E, Mistretta FA, Knipper S, Palumbo C, et al
    Long-Term Incidence of Secondary Bladder, Rectal Cancer in Patients Treated with Brachytherapy for Localized Prostate Cancer: A Large-Scale Population-Based Analysis.
    BJU Int. 2019 May 30. doi: 10.1111/bju.14841.
    PubMed     Abstract available


  64. WARD DG, Gordon NS, Boucher RH, Pirrie SJ, et al
    Targeted deep sequencing of urothelial bladder cancers and associated urinary DNA: a 23-gene panel with utility for non-invasive diagnosis and risk stratification.
    BJU Int. 2019 May 11. doi: 10.1111/bju.14808.
    PubMed     Abstract available


  65. YU EY, Nekeman D, Aaronson NK, Billingham LJ, et al
    Health-Related Quality of Life in Bladder Cancer Patients around the Time of Diagnosis.
    BJU Int. 2019 May 11. doi: 10.1111/bju.14804.
    PubMed     Abstract available


  66. SEILER R, Wyatt AW, Black PC
    Molecular landscape of muscle-invasive bladder cancer: Patient age matter?
    BJU Int. 2019 May 9. doi: 10.1111/bju.14802.
    PubMed     Abstract available


  67. MOSSANEN M, Kibel AS
    The bladder cancer conundrum: how do we treat the right tumour with the right treatment, at the right time?
    BJU Int. 2019;123:748-749.
    PubMed    


    March 2019
  68. KHETRAPAL P, Kelly JD, Catto JWF, Vasdev N, et al
    Does the robot have a role in radical cystectomy?
    BJU Int. 2019;123:380-382.
    PubMed    


    February 2019
  69. KIJIMA T, Tanaka H, Koga F, Masuda H, et al
    Selective Tetramodal Bladder Preservation Therapy Incorporating Induction Chemoradiotherapy and Consolidative Partial Cystectomy with Pelvic Lymph Node Dissection for Muscle-Invasive Bladder Cancer: Oncological and Functional Outcomes of 107 Patients.
    BJU Int. 2019 Feb 27. doi: 10.1111/bju.14736.
    PubMed     Abstract available


  70. TARIQ A, Khan SR, Vela I, Williams ED, et al
    Assessment of bladder cancer patients and carers use of internet, social media and quality of available patient centric online resources: A systematic review.
    BJU Int. 2019 Feb 24. doi: 10.1111/bju.14720.
    PubMed     Abstract available


  71. HUGAR LA, Lopa SH, Yabes JG, Yu JA, et al
    Palliative Care Use Among Patients with Bladder Cancer.
    BJU Int. 2019 Feb 13. doi: 10.1111/bju.14708.
    PubMed     Abstract available


  72. DHARIWAL R, Pindoria N, Dasgupta P, Khan MS, et al
    #Checkmate: could checkpoint inhibitors be the game changer in the fight against metastatic urothelial carcinoma?
    BJU Int. 2019;123:203-207.
    PubMed    


  73. NURMINEN P, Ettala O, Seppanen M, Taimen P, et al
    Urine cytology is a feasible tool for assessing erythematous bladder lesions after bacille Calmette-Guerin (BCG) treatment.
    BJU Int. 2019;123:246-251.
    PubMed     Abstract available


  74. KINNEAR N, O'Callaghan M, Hennessey D, Liddell H, et al
    Intra-operative cell salvage in urological surgery: a systematic review and meta-analysis of comparative studies.
    BJU Int. 2019;123:210-219.
    PubMed     Abstract available


    January 2019
  75. TAN WS, Teo CH, Chan D, Heinrich M, et al
    Mix methods approach to explore patients' perspectives on the acceptability of a urinary biomarker test in replacement of cystoscopy in bladder cancer surveillance.
    BJU Int. 2019 Jan 29. doi: 10.1111/bju.14690.
    PubMed     Abstract available


  76. BAJIC P, Wolfe AJ, Gupta GN
    Old Instillations and New Implications in Bladder Cancer: The Urinary Microbiome and Intravesical BCG.
    BJU Int. 2019 Jan 21. doi: 10.1111/bju.14683.
    PubMed     Abstract available


  77. D'ANDREA D, Soria F, Zehetmayer S, Gust KM, et al
    Diagnostic accuracy, clinical utility and influence on decision making of a methylation urine biomarker test in the surveillance of non-muscle-invasive bladder cancer.
    BJU Int. 2019 Jan 17. doi: 10.1111/bju.14673.
    PubMed     Abstract available


  78. BOERI L, Soligo M, Frank I, Boorjian SA, et al
    Cigarette smoking is associated with adverse pathological response and increased disease recurrence amongst patients with muscle-invasive bladder cancer treated with cisplatin-based neoadjuvant chemotherapy and radical cystectomy: a single-centre expe
    BJU Int. 2019 Jan 8. doi: 10.1111/bju.14612.
    PubMed     Abstract available


  79. TAN WS, Sarpong R, Khetrapal P, Rodney S, et al
    Does urinary cytology have a role in haematuria investigations?
    BJU Int. 2019;123:74-81.
    PubMed     Abstract available


    December 2018
  80. MUNARI E, Calio A, Brunelli M, Martignoni G, et al
    Predicting progression in T1 non-muscle-invasive bladder cancer: back to histology.
    BJU Int. 2018;122:914-915.
    PubMed    


    October 2018
  81. QU LG, Lawrentschuk N
    Bladder cancer surveillance in patients with spinal cord injuries.
    BJU Int. 2018 Oct 8. doi: 10.1111/bju.14582.
    PubMed     Abstract available


  82. SOLOWAY MS
    Postoperative intravesical chemotherapy has an important role in reducing subsequent bladder tumours - why is it not routine?
    BJU Int. 2018;122:525-526.
    PubMed    


    September 2018
  83. SUAREZ-IBARROLA R, Soria F, Abufaraj M, D'Andrea D, et al
    Surgical checklist impact on recurrence-free survival of non-muscle invasive bladder cancer patients undergoing transurethral resection of bladder tumor.
    BJU Int. 2018 Sep 24. doi: 10.1111/bju.14557.
    PubMed     Abstract available


    August 2018
  84. LANE G, Risk M, Fan Y, Krishna S, et al
    Persistent muscle invasive bladder cancer after neoadjuvant chemotherapy: An analysis of SEER-Medicare data.
    BJU Int. 2018 Aug 20. doi: 10.1111/bju.14529.
    PubMed     Abstract available


  85. BREYER J, Wirtz RM, Erben P, Rinaldetti S, et al
    FOXM1 overexpression is associated with adverse outcome and predicts response to intravesical instillation therapy in stage pT1 non-muscle-invasive bladder cancer (NMIBC).
    BJU Int. 2018 Aug 18. doi: 10.1111/bju.14525.
    PubMed     Abstract available


  86. HEIJNSDIJK EAM, Nieboer D, Garg T, Lansdorp-Vogelaar I, et al
    Cost-effectiveness of surveillance schedules in older adults with non-muscle-invasive bladder cancer.
    BJU Int. 2018 Aug 1. doi: 10.1111/bju.14502.
    PubMed     Abstract available


  87. GROSS T, Furrer M, Schorno P, Wuethrich PY, et al
    Reproductive organ-sparing cystectomy significantly improves continence in women after orthotopic bladder substitution without affecting oncological outcome.
    BJU Int. 2018;122:227-235.
    PubMed     Abstract available


    July 2018
  88. SMITH A, Daneshmand S, Patel S, Pohar K, et al
    Patient-reported Outcomes of Blue Light Flexible Cystoscopy with Hexaminolevulinate (HAL) in the Surveillance of Bladder Cancer: Results from a Prospective Multi-center Study.
    BJU Int. 2018 Jul 6. doi: 10.1111/bju.14481.
    PubMed     Abstract available


  89. MMEJE CO, Benson CR, Nogueras-Gonzalez GM, Jayaratna IS, et al
    Determining the optimal time for radical cystectomy after neoadjuvant chemotherapy.
    BJU Int. 2018;122:89-98.
    PubMed     Abstract available


    June 2018
  90. JEFFERIES ER, Cresswell J, McGrath JS, Miller C, et al
    Open radical cystectomy in England: the current standard of care - an analysis of the British Association of Urological Surgeons (BAUS) cystectomy audit and Hospital Episodes Statistics (HES) data.
    BJU Int. 2018;121:880-885.
    PubMed     Abstract available


    May 2018
  91. MARI A, Kimura S, Foerster B, Abufaraj M, et al
    A Systematic Review and Meta-Analysis of the impact of Lymphovascular Invasion in Bladder Cancer Transurethral Resection Specimens.
    BJU Int. 2018 May 28. doi: 10.1111/bju.14417.
    PubMed     Abstract available


  92. EREDICS K, Bretterbauer KM, Comploj E, Friedl A, et al
    Bladder cancer in nonagenarians:a multicenter study of 123 patients.
    BJU Int. 2018 May 27. doi: 10.1111/bju.14419.
    PubMed     Abstract available


  93. NA R, Wu Y, Jiang G, Yu H, et al
    Germline Mutations in DNA Repair Genes are Associated with Bladder Cancer Risk and Unfavorable Prognosis.
    BJU Int. 2018 May 4. doi: 10.1111/bju.14370.
    PubMed     Abstract available


  94. GANDHI N, Krishna S, Booth CM, Breau RH, et al
    Diagnostic accuracy of MRI for tumor staging of bladder cancer: Systematic review and Meta-Analysis.
    BJU Int. 2018 May 4. doi: 10.1111/bju.14366.
    PubMed     Abstract available


  95. MASON SJ, Catto JW, Downing A, Bottomley SE, et al
    Evaluating Patient Reported Outcome Measures (PROMs) for bladder cancer: a systematic review using the COSMIN checklist.
    BJU Int. 2018 May 3. doi: 10.1111/bju.14368.
    PubMed     Abstract available


  96. BRASSETTI A, Moller A, Laurin O, Hoijer J, et al
    Evolution of cystectomy care over an 11-year period in a high-volume tertiary referral centre.
    BJU Int. 2018;121:752-757.
    PubMed     Abstract available


    April 2018
  97. FRANSEN VAN DE PUTTE EE, Bosschieter J, van der Kwast TH, Bertz S, et al
    The WHO 1973 classification system for grade is an Important prognosticator in T1 non-muscle-invasive bladder cancer.
    BJU Int. 2018 Apr 10. doi: 10.1111/bju.14238.
    PubMed     Abstract available


  98. CHA EK, Sfakianos JP, Sukhu R, Yee AM, et al
    Poor prognosis of bladder cancer patients with occult lymph node metastases treated with neoadjuvant chemotherapy.
    BJU Int. 2018 Apr 7. doi: 10.1111/bju.14242.
    PubMed     Abstract available


  99. MOSSANEN M, Brown JC, Schrag D
    Well-being beyond the bladder. How do we improve the overall health of patients with bladder cancer?
    BJU Int. 2018;121:489-491.
    PubMed    


  100. GOFRIT ON, Pode D, Pizov G, Duvdevani M, et al
    'Very-low-risk' bladder tumours - a new entity?
    BJU Int. 2018;121:627-631.
    PubMed     Abstract available


  101. TAN WS, Tan MY, Lamb BW, Sridhar A, et al
    Intracorporeal robot-assisted radical cystectomy, together with an enhanced recovery programme, improves postoperative outcomes by aggregating marginal gains.
    BJU Int. 2018;121:632-639.
    PubMed     Abstract available


    March 2018
  102. LOTAN Y, Woldu SL, Sanli O, Black P, et al
    Modeling Cost-Effectiveness of a Biomarker-Based Approach to Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer.
    BJU Int. 2018 Mar 31. doi: 10.1111/bju.14220.
    PubMed     Abstract available


  103. MOSSANEN M, Krasnow RE, Lipsitz SR, Preston MA, et al
    Associations of specific postoperative complications with costs after radical cystectomy.
    BJU Int. 2018;121:428-436.
    PubMed     Abstract available


    February 2018
  104. SEISEN T
    Examining the role of centralisation of radical cystectomy for bladder cancer.
    BJU Int. 2018;121:165-167.
    PubMed    


  105. MINERVINI A, Vanacore D, Vittori G, Milanesi M, et al
    Florence robotic intracorporeal neobladder (FloRIN): a new reconfiguration strategy developed following the IDEAL guidelines.
    BJU Int. 2018;121:313-317.
    PubMed     Abstract available


  106. PERERA M, Papa N, Christidis D, McGrath S, et al
    The impact of the global bacille Calmette-Guerin shortage on treatment patterns: population-based data.
    BJU Int. 2018;121:169-172.
    PubMed    


  107. GUO RQ, Hong P, Xiong GY, Zhang L, et al
    Impact of ureteroscopy before radical nephroureterectomy for upper tract urothelial carcinomas on oncological outcomes: a meta-analysis.
    BJU Int. 2018;121:184-193.
    PubMed     Abstract available


    January 2018
  108. BOSSCHIETER J, van Moorselaar RJA, Vis AN, van Ginkel T, et al
    The Effect of Timing of an Immediate Instillation with Mitomycin C after Transurethral Resection in 941 Non Muscle-invasive Bladder Cancer Patients.
    BJU Int. 2018 Jan 10. doi: 10.1111/bju.14124.
    PubMed     Abstract available


  109. SU J, Zhu Q, Yuan L, Zhang Y, et al
    Transumbilical laparoendoscopic single-site radical prostatectomy and cystectomy with the aid of a transurethral port: a feasibility study.
    BJU Int. 2018;121:111-118.
    PubMed     Abstract available


    December 2017
  110. MIYAKE M, Tatsumi Y, Matsumoto H, Nagao K, et al
    Outcomes of subsequent non-muscle invasive bladder cancer treated with intravesical Bacillus Calmette-Guerin after radical nephroureterectomy for upper urinary tract urothelial carcinoma: A propensity matched analysis with primary bladder cancer.
    BJU Int. 2017 Dec 27. doi: 10.1111/bju.14111.
    PubMed     Abstract available


  111. RITCH CR, Balise R, Soodana Prakash N, Alonzo D, et al
    Propensity matched comparative analysis of survival following chemoradiation or radical cystectomy for muscle invasive bladder cancer.
    BJU Int. 2017 Dec 27. doi: 10.1111/bju.14109.
    PubMed     Abstract available



  112. Bladder cancer: diagnosis and management of bladder cancer: (c) NICE (2015) Bladder cancer: diagnosis and management of bladder cancer.
    BJU Int. 2017;120:755-765.
    PubMed    


  113. MAURICE MJ, Kaouk JH
    Robotic radical perineal cystectomy and extended pelvic lymphadenectomy: initial investigation using a purpose-built single-port robotic system.
    BJU Int. 2017;120:881-884.
    PubMed     Abstract available


  114. DASGUPTA P
    NICE guidance and the BJUI.
    BJU Int. 2017;120:743.
    PubMed    


  115. VAN HEMELRIJCK M
    Human development and its impact on genitourinary cancers.
    BJU Int. 2017;120:747-748.
    PubMed    


    November 2017
  116. AHMADI N, Clifford TG, Miranda G, Cai J, et al
    Impact of body mass index on robot-assisted radical cystectomy with intracorporeal urinary diversion.
    BJU Int. 2017;120:689-694.
    PubMed     Abstract available


  117. HUDDART RA, Birtle A, Maynard L, Beresford M, et al
    Clinical and patient-reported outcomes of SPARE - a randomised feasibility study of selective bladder preservation versus radical cystectomy.
    BJU Int. 2017;120:639-650.
    PubMed     Abstract available


  118. KINNEAR N, Smith R, Hennessey DB, Bolton D, et al
    Implementation rates of uro-oncology multidisciplinary meeting decisions.
    BJU Int. 2017;120 Suppl 3:15-20.
    PubMed     Abstract available


  119. STRATTON K
    Cystectomy for cT4 prostate cancer: the most radical treatment.
    BJU Int. 2017;120.
    PubMed    


    October 2017
  120. XIA L, Taylor BL, Newton AD, Malhotra A, et al
    Early Discharge and Post-Discharge Outcomes in Patients Undergoing Radical Cystectomy for Bladder Cancer.
    BJU Int. 2017 Oct 24. doi: 10.1111/bju.14058.
    PubMed     Abstract available


  121. SMITH AB, Jaeger B, Pinheiro LC, Edwards LJ, et al
    The impact of bladder cancer on health-related quality of life.
    BJU Int. 2017 Oct 8. doi: 10.1111/bju.14047.
    PubMed     Abstract available


  122. LIEDBERG F, Gudjonsson S, Xu A, Bendahl PO, et al
    Long-term third-party assessment of results after continent cutaneous diversion with Lundiana pouch.
    BJU Int. 2017;120:530-536.
    PubMed     Abstract available


    September 2017
  123. PICHLER R, Fritz J, Tulchiner G, Klinglmair G, et al
    Increased Accuracy of a novel mRNA-based Urine Test for Bladder Cancer Surveillance.
    BJU Int. 2017 Sep 20. doi: 10.1111/bju.14019.
    PubMed     Abstract available


  124. VETTERLEIN MW, Gild P, Kluth LA, Seisen T, et al
    Perioperative Allogeneic Blood Transfusion Does Not Adversely Impact Oncological Outcomes After Radical Cystectomy for Urinary Bladder Cancer - a Propensity Score-weighted European Multicenter Study.
    BJU Int. 2017 Sep 14. doi: 10.1111/bju.14012.
    PubMed     Abstract available


  125. LI R, Metcalfe MJ, Ferguson Rd JE, Mokkapati S, et al
    Effects of Thiazolidinedione in Patients with Active Bladder Cancer.
    BJU Int. 2017 Sep 5. doi: 10.1111/bju.14009.
    PubMed     Abstract available


  126. DUDDERIDGE T
    Positive messages for bladder cancer management in negative sentinel lymph node study.
    BJU Int. 2017;120:302-303.
    PubMed    


  127. MARCHIONI M, Primiceri G, Cindolo L, Hampton LJ, et al
    Impact of diagnostic ureteroscopy on intravesical recurrence in patients undergoing radical nephroureterectomy for upper tract urothelial cancer: a systematic review and meta-analysis.
    BJU Int. 2017;120:313-319.
    PubMed     Abstract available


  128. BLUTE ML JR, Kucherov V, Rushmer TJ, Damodaran S, et al
    Reduced estimated glomerular filtration rate (eGFR <60 mL/min/1.73 m2 ) at first transurethral resection of bladder tumour is a significant predictor of subsequent recurrence and progression.
    BJU Int. 2017;120:387-393.
    PubMed     Abstract available


  129. CHAPPIDI MR, Kates M, Tosoian JJ, Johnson MH, et al
    Evaluation of gender-based disparities in time from initial haematuria presentation to upper tract urothelial carcinoma diagnosis: analysis of a nationwide insurance claims database.
    BJU Int. 2017;120:377-386.
    PubMed     Abstract available


    August 2017
  130. WAINGANKAR N, Mallin K, Smaldone M, Egleston BL, et al
    Assessing the relative influence of hospital and surgeon volume on short-term mortality after radical cystectomy.
    BJU Int. 2017;120:239-245.
    PubMed     Abstract available


  131. MILLER C, Campain NJ, Dbeis R, Daugherty M, et al
    Introduction of robot-assisted radical cystectomy within an established enhanced recovery programme.
    BJU Int. 2017;120:265-272.
    PubMed     Abstract available


  132. CATTO JWF
    Speeding up recovery from radical cystectomy: how low can we go?
    BJU Int. 2017;120:162-163.
    PubMed    


    June 2017
  133. MCCOMBIE SP, Bangash HK, Kuan M, Thyer I, et al
    Delays in the diagnosis and initial treatment of bladder cancer in Western Australia.
    BJU Int. 2017 Jun 29. doi: 10.1111/bju.13939.
    PubMed     Abstract available


  134. AFSHAR M, Goodfellow H, Jackson-Spence F, Evison F, et al
    Centralisation of radical cystectomies for bladder cancer in England, a decade on from the 'Improving Outcomes Guidance': The case for super centralisation.
    BJU Int. 2017 Jun 8. doi: 10.1111/bju.13929.
    PubMed     Abstract available


  135. SOAVE A, Riethdorf S, Dahlem R, Minner S, et al
    Detection and oncological effect of circulating tumour cells in patients with variant urothelial carcinoma histology treated with radical cystectomy.
    BJU Int. 2017;119:854-861.
    PubMed     Abstract available


  136. KOCH MO
    Detection and oncological effect of circulating tumour cells in patients with variant urothelial carcinoma histology treated with radical cystectomy.
    BJU Int. 2017;119:816.
    PubMed    


    May 2017
  137. NGO B, Papa N, Perera M, Bolton D, et al
    Bladder cancer diagnosis during haematuria investigation - implications for practice guidelines.
    BJU Int. 2017;119 Suppl 5:53-54.
    PubMed    


  138. HAYNE D
    Bladder cancer - Old lessons yet to be learned.
    BJU Int. 2017;119 Suppl 5:7.
    PubMed    


  139. NGO B, Perera M, Papa N, Bolton D, et al
    Factors affecting the timeliness and adequacy of haematuria assessment in bladder cancer: a systematic review.
    BJU Int. 2017;119 Suppl 5:10-18.
    PubMed     Abstract available


  140. LAWRENTSCHUK N
    Bladder cancer- time for a higher profile in our region.
    BJU Int. 2017;119 Suppl 5:5.
    PubMed    


  141. NGO B, Papa N, Perera M, Bolton D, et al
    Predictors of delay to cystoscopy and adequacy of investigations in patients with haematuria.
    BJU Int. 2017;119 Suppl 5:19-25.
    PubMed     Abstract available


  142. VON LANDENBERG N, Speed JM, Trinh QD
    Do micropapillary patients benefit from chemotherapy?
    BJU Int. 2017;119:656-658.
    PubMed    


  143. DAVIS JW
    Biomarker classification, validation, and what to look for in 2017 and beyond.
    BJU Int. 2017;119:812-814.
    PubMed    


    April 2017
  144. HAYNE D, Stockler M, McCombie SP, Lawrence N, et al
    The BCG + Mitomycin trial for high risk non-muscle-invasive bladder cancer: Progress report and lessons learned.
    BJU Int. 2017 Apr 9. doi: 10.1111/bju.13873.
    PubMed     Abstract available


  145. BAILEY GC, Boorjian SA, Ziegelmann MJ, Westerman ME, et al
    Urinary collecting system invasion is associated with poor survival in patients with clear-cell renal cell carcinoma.
    BJU Int. 2017;119:585-590.
    PubMed     Abstract available


  146. HINATA N, Hussein AA, George S, Trump DL, et al
    Impact of suboptimal neoadjuvant chemotherapy on peri-operative outcomes and survival after robot-assisted radical cystectomy: a multicentre multinational study.
    BJU Int. 2017;119:605-611.
    PubMed     Abstract available


    February 2017
  147. VESKIMAE E, Neuzillet Y, Rouanne M, MacLennan S, et al
    Systematic review of the oncological and functional outcomes of pelvic organ-preserving cystectomy compared with standard radical cystectomy in women who undergo curative surgery and orthotopic neobladder substitution for bladder cancer.
    BJU Int. 2017 Feb 20. doi: 10.1111/bju.13819.
    PubMed     Abstract available


  148. SPAHN M, Morlacco A, Boxler S, Joniau S, et al
    Outcome predictors of radical cystectomy in patients with cT4 prostate cancer: A multi-institutional study of 62 patients.
    BJU Int. 2017 Feb 20. doi: 10.1111/bju.13818.
    PubMed     Abstract available


    January 2017
  149. WOLDU SL, Bagrodia A, Lotan Y
    Guideline of Guidelines - Non-Muscle Invasive Bladder Cancer.
    BJU Int. 2017 Jan 6. doi: 10.1111/bju.13760.
    PubMed     Abstract available


  150. GOLOMBOS DM, O'Malley P, Lewicki P, Stone BV, et al
    Robot-assisted partial cystectomy: perioperative outcomes and early oncological efficacy.
    BJU Int. 2017;119:128-134.
    PubMed     Abstract available


  151. THALMANN GN
    Quality improvement in cystectomy care with enhanced recovery (QUICCER) study.
    BJU Int. 2017;119:4-5.
    PubMed    


    December 2016
  152. HUSSEIN AA, Hinata N, Dibaj S, May PR, et al
    Development, Validation and Clinical Application of Pelvic Lymphadenectomy Assessment and Completion Evaluation (PLACE): Intraoperative Assessment of Lymph Node Dissection after Robot-Assisted Radical Cystectomy for Bladder Cancer.
    BJU Int. 2016 Dec 17. doi: 10.1111/bju.13748.
    PubMed     Abstract available


    October 2016
  153. ALJABERY F, Shabo I, Olson H, Gimm O, et al
    Radio-guided sentinel lymph node detection and lymph node mapping in invasive urinary bladder cancer-a prospective clinical study.
    BJU Int. 2016 Oct 31. doi: 10.1111/bju.13700.
    PubMed     Abstract available


  154. FERNANDEZ MI, Williams SB, Willis DL, Slack RS, et al
    Clinical Risk Stratification in Patients with Surgically Resectable Micropapillary Bladder Cancer.
    BJU Int. 2016 Oct 18. doi: 10.1111/bju.13689.
    PubMed     Abstract available


  155. MATARAZA JM, Gotwals P
    Recent advances in immuno-oncology and its application to urological cancers.
    BJU Int. 2016;118:506-14.
    PubMed     Abstract available


  156. LONGO N, Imbimbo C, Fusco F, Ficarra V, et al
    Complications and quality of life in elderly patients with several comorbidities undergoing cutaneous ureterostomy with single stoma or ileal conduit after radical cystectomy.
    BJU Int. 2016;118:521-6.
    PubMed     Abstract available


  157. ZHANG C, Ma X, Du J, Yao Z, et al
    MicroRNA-30a as a prognostic factor in urothelial carcinoma of bladder inhibits cellular malignancy by antagonising Notch1.
    BJU Int. 2016;118:578-89.
    PubMed     Abstract available


    June 2016
  158. MEYER CP, Rios Diaz AJ, Dalela D, Hanske J, et al
    Wound dehiscence in a sample of 1 776 cystectomies: identification of predictors and implications for outcomes.
    BJU Int. 2016;117.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Bladder Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: